HLA-A and neoplasm: We first produced 6 dsSCDs matching the HLA-A,B,C allotypes of that patient and employed them in the newly developed MediMer peptide binding assay to screen a large panel of potential neoepitope peptides, peptides derived from shared tumor-associated antigens as well as known viral epitopes for in vitro binding to dsSCD and easYmers (see Figure 6D).